Search research articles
Contact Us
Filters
Showing results (81-90 of 99) with videos related to
Page
of 10
Sort By:
Magnetic Resonance in Medicine
|
December 14, 2021
Characterization of the diffusion signal of breast tissues using multi-exponential models
Ana E Rodríguez-Soto, Maren M Sjaastad Andreassen, Lauren K Fang, et al.
Breast Cancer Research and Treatment
|
December 3, 2024
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
Hope S Rugo, Mike Campbell, Christina Yau, et al.
Annals of Surgical Oncology
|
July 12, 2024
Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial
Kayla M Switalla, Judy C Boughey, Katrina Dimitroff, et al.
Annals of Surgical Oncology
|
August 23, 2025
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial
Julie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Annals of Surgical Oncology
|
August 29, 2025
ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial
Julie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
JAMA Surgery
|
September 7, 2022
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial
Marie Osdoit, Christina Yau, W Fraser Symmans, et al.
JAMA Network Open
|
December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
Beverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
The New England Journal of Medicine
|
July 14, 2016
Adaptive Randomization of Neratinib in Early Breast Cancer
John W Park, Minetta C Liu, Douglas Yee, et al.
Cancer Cell
|
June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M Wolf, et al.
The New England Journal of Medicine
|
July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
Hope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 99) with videos related to
Sort By:
Page
of 10
Magnetic Resonance in Medicine
|
December 14, 2021
Characterization of the diffusion signal of breast tissues using multi-exponential models
Ana E Rodríguez-Soto, Maren M Sjaastad Andreassen, Lauren K Fang, et al.
Breast Cancer Research and Treatment
|
December 3, 2024
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
Hope S Rugo, Mike Campbell, Christina Yau, et al.
Annals of Surgical Oncology
|
July 12, 2024
Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial
Kayla M Switalla, Judy C Boughey, Katrina Dimitroff, et al.
Annals of Surgical Oncology
|
August 23, 2025
Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial
Julie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
Annals of Surgical Oncology
|
August 29, 2025
ASO Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial
Julie Van Hassel, Katrina Dimitroff, Christina Yau, et al.
JAMA Surgery
|
September 7, 2022
Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial
Marie Osdoit, Christina Yau, W Fraser Symmans, et al.
JAMA Network Open
|
December 28, 2023
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
Beverly Kyalwazi, Christina Yau, Michael J Campbell, et al.
The New England Journal of Medicine
|
July 14, 2016
Adaptive Randomization of Neratinib in Early Breast Cancer
John W Park, Minetta C Liu, Douglas Yee, et al.
Cancer Cell
|
June 18, 2021
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M Wolf, et al.
The New England Journal of Medicine
|
July 14, 2016
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer
Hope S Rugo, Olufunmilayo I Olopade, Angela DeMichele, et al.
Page
of 10